Skip to main content
. 2014 Aug 19;56(3):594–601. doi: 10.3109/10428194.2014.911863

Figure 2.

Figure 2.

Effect of risk groups derived from the REL-17 signature on PFS and OS. In the training set, 15.1% cases being identified as having more than 60% chance to relapse within 1 year had significantly shorter PFS (A; median 13.8 vs. 34.8 months, p < 10− 16) and OS (B; median 29.9 vs. 88.1 months, p = 2.39 × 10− 14) in contrast to those at lower risk. Using the same criteria 12.3% patients being identified at high risk in the test set also had significantly shorter PFS (C; median 15.9 vs. 40.5 months, p = 10− 7) and OS (D; median 53 months vs. not reached, p = 0.0003) compared to rest of the cases.